DDX37 Inhibitors

The chemical class known as DDX37 inhibitors comprises a set of diverse compounds strategically designed to modulate cellular processes linked to DDX37. One such inhibitor is 5-Fluorouracil, an antimetabolite disrupting DNA synthesis by altering nucleotide metabolism. This action may indirectly impact pathways associated with DDX37 modulation, given the intricate relationship between nucleotide metabolism and RNA helicases like DDX37. Actinomycin D, a transcription inhibitor, interferes with RNA synthesis, impacting processes associated with DDX37. Similarly, Etoposide, a Topoisomerase II inhibitor, alters DNA topology, affecting processes linked to DDX37 function. These compounds showcase the intricate interplay between nucleotide metabolism, DNA synthesis, and DDX37-related processes.

In addition to direct inhibitors, platinum-based compounds like Cisplatin induce DNA damage, influencing DDX37 through their impact on DNA repair mechanisms. Thalidomide, an immunomodulatory agent, modulates cytokine profiles and immune responses, indirectly influencing pathways related to DDX37. These compounds highlight the multifaceted approaches employed to modulate cellular processes associated with DDX37, providing valuable tools for further research into the intricacies of RNA helicase function. The diverse mechanisms of action of these inhibitors offer a rich tapestry of insights into regulatory networks linked to DDX37 and underscore the importance of understanding their specific impacts on cellular pathways.